JP2025503251A - 治療薬 - Google Patents

治療薬 Download PDF

Info

Publication number
JP2025503251A
JP2025503251A JP2024544873A JP2024544873A JP2025503251A JP 2025503251 A JP2025503251 A JP 2025503251A JP 2024544873 A JP2024544873 A JP 2024544873A JP 2024544873 A JP2024544873 A JP 2024544873A JP 2025503251 A JP2025503251 A JP 2025503251A
Authority
JP
Japan
Prior art keywords
agent
inhibitor
protein
nlpd
pyelonephritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503251A5 (https=
JPWO2023144341A5 (https=
Inventor
スバンボリィ，カタリーナ
アンビテ，イネス
Original Assignee
セレクティミューン ファーマ アクチエボラグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレクティミューン ファーマ アクチエボラグ filed Critical セレクティミューン ファーマ アクチエボラグ
Publication of JP2025503251A publication Critical patent/JP2025503251A/ja
Publication of JP2025503251A5 publication Critical patent/JP2025503251A5/ja
Publication of JPWO2023144341A5 publication Critical patent/JPWO2023144341A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024544873A 2022-01-28 2023-01-27 治療薬 Pending JP2025503251A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2201139.9 2022-01-28
GBGB2201139.9A GB202201139D0 (en) 2022-01-28 2022-01-28 Therapeutic agent
PCT/EP2023/052076 WO2023144341A1 (en) 2022-01-28 2023-01-27 Therapeutic agent

Publications (3)

Publication Number Publication Date
JP2025503251A true JP2025503251A (ja) 2025-01-30
JP2025503251A5 JP2025503251A5 (https=) 2026-02-04
JPWO2023144341A5 JPWO2023144341A5 (https=) 2026-02-04

Family

ID=80621245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544873A Pending JP2025503251A (ja) 2022-01-28 2023-01-27 治療薬

Country Status (7)

Country Link
US (1) US20250241990A1 (https=)
EP (1) EP4469153A1 (https=)
JP (1) JP2025503251A (https=)
CN (1) CN119156222A (https=)
AU (1) AU2023213106A1 (https=)
GB (1) GB202201139D0 (https=)
WO (1) WO2023144341A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119936405A (zh) * 2025-01-23 2025-05-06 上海市重大传染病和生物安全研究院 血浆IL-1Ra作为生物标志物在儿童脓毒症诊断和预后中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA761627B (en) 1976-03-16 1978-01-25 C Friedmann Improvements in or relating to the treatment of arthritis
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
GB201617548D0 (en) * 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor

Also Published As

Publication number Publication date
CN119156222A (zh) 2024-12-17
WO2023144341A1 (en) 2023-08-03
GB202201139D0 (en) 2022-03-16
AU2023213106A1 (en) 2024-09-12
US20250241990A1 (en) 2025-07-31
EP4469153A1 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
JP7386455B2 (ja) 乾癬の治療薬
JP2002220342A (ja) インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
EP3551187B1 (en) Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with olodaterol
CN111542335A (zh) 炎症性肠病的治疗药
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
KR20040040489A (ko) 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료
JPH06507386A (ja) 治療用ペプチド
JP2025503251A (ja) 治療薬
JP3538616B2 (ja) 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法
JP2006514001A (ja) 痛み軽減薬剤
JPWO2001080891A1 (ja) 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法
KR20220051418A (ko) 근위축성 측삭 경화증 치료제
US20250235506A1 (en) Chimeric il-10/carrier constructs for treatment of pouchitis and methods of use
JP2025506869A (ja) 特発性肺線維症の処置のための組成物及び方法
TWI752110B (zh) 腦梗塞的治療藥
KR20220111620A (ko) 코비드-19 감염증의 예방 또는 치료용 약제학적 조성물
WO2007060440A2 (en) The use of peptides in anti-ulcer therapy
JP7813293B2 (ja) コロナウイルス治療法
JP2004002454A (ja) 消化管運動抑制剤
JP2002179588A (ja) チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤
JP2009108042A (ja) アゼラスチンとアンブロキソールとを含有する医薬組成物
US11161881B2 (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
WO2007118431A1 (zh) Trap 蛋白自身作为活性成分在制备治疗金黄色葡萄球菌感染的药物中的应用
JP3640254B2 (ja) 間質性肺炎治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260123